Podcasts about ii iii

  • 199PODCASTS
  • 389EPISODES
  • 43mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • Dec 30, 2022LATEST

POPULARITY

20152016201720182019202020212022


Best podcasts about ii iii

Show all podcasts related to ii iii

Latest podcast episodes about ii iii

Orthodox Wisdom
Christianity or the Church? - St. Hilarion Troitsky (Pt. II/III)

Orthodox Wisdom

Play Episode Listen Later Dec 30, 2022 38:19


Part II of "Christianity or the Church?" Read the text here: http://orthodoxinfo.com/inquirers/sthilarion_church.asp 0:05 To be a Christian means to belong to the visible Church and obey Her hierarchs 1:10 Heretics and schismatics do not have the true, unifying love of God 2:00 Not only no Christian love outside the Church, but no Christian teaching in the true sense 3:32 According to Saint Cyprian, to be outside the Church and yet remain a Christian is impossible, for to be outside the Church is to be outside Christ's camp. 4:46 St. Cyprian: "He who does not have the Church as his mother cannot have God as his Father." 5:13 For this reason St. Cyprian called for schismatics to enter the Church by baptism 6:07 Council of Carthage 256 (and later the 6th EC in Trullo) affirms St. Cyprian's canon though modified his view that all schismatics should be received by baptism. “On this point, the views of Blessed Augustine differ somewhat, although his view of the relationship of Christianity to the Church remains exactly the same.” 7:27 The teaching of Blessed Augustine 8:18 If schismatics retain true baptism, is the Church necessary? Is salvation possible outside the Church? Bl. Augustine answers “No.” 9:03 St. Hilarion repeating Bl. Augustine: “All the wealth of the Church which is possessed by those who have separated themselves from the Church brings them absolutely no benefit, but only harm.” 11:39 “Schismatics are deprived of the hope of salvation not only because their baptism is invalid, but also because they are outside the Church and in enmity with it.” 13:28 “The points of view of Saint Cyprian and Blessed Augustine can be seen to differ somewhat, but they both arrive at exactly the same conclusion: outside the Church there is no salvation!” 15:00 Christ is not only a great teacher, but the Savior of the world. He gave life, not merely teaching 15:48 On the ninth article of the Creed: “[I believe] in One, Holy, Catholic, and Apostolic Church” 16:40 The concept of the Church, not Christianity, lay at the head of Christian beliefs from the beginning 17:11 The falsification of the Church with Christianity 18:19 “Thus it seems that we will not err if we express the thought that the truth of the Church, above all other truths, touches the very life of each Christian, defining not only his beliefs, but also his life.” 18:59 Western influence on Russian Society 20:23 Protestantism was created from Latinism and is a purely human creation 21:28 St. Hilarion identifies the Church with love and those who have broken off do not have the love of God in the Church 22:06 “Protestantism placed a papal tiara on every German professor…” 22:48 “The human soul is Church-prone by nature.” 23:04 “Self-love and Self-will received a sort of sanctification and blessing from Protestantism.” 24:02 Individualism blossoms in Protestantism in the West 25:22 Russian Literature has suffered from Protestantism's influence as well 26:22 The Russian people have lost the habit of being Church-minded 27:33 This de-Churchification is a “subtle venom” 28:51 Wisdom from St. Vincent of Lérins 29:29 Christ left no system, no writings, and “there is nothing easier than to re-interpret Christ's teaching according to one's personal taste and to invent "Christianity," passing off, under this name, the dreams of one's heart and the images of one's own idle fantasy.” 32:58 When Christianity = The Church then Christ the God-Man = Jesus of Nazareth --- Send in a voice message: https://anchor.fm/orthodox-wisdom/message

Church of Jesus Christ Study Session with Come Follow Me
S4 E335-E336 CFM Dec 12 - Dec 18 Part II-III

Church of Jesus Christ Study Session with Come Follow Me

Play Episode Listen Later Dec 16, 2022 14:20


Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

The Joy of Gaming Podcast
Episode Twelve - God of War Franchise Retrospective (2005-2022)

The Joy of Gaming Podcast

Play Episode Listen Later Dec 2, 2022 94:45


The (New) Joy of Gaming Podcast - Episode Twelve God of War Franchise Retrospective (2005-2022) On this episode of The (New) Joy of Gaming Podcast, we continue our God of War: Ragnarok Celebration, this time taking a trip down memory lane with Kratos as he murdered his way through hordes of Greek and Norse Gods, and somehow found his way into our hearts. From its introduction in 2005 with God of War on PS2, through three console generations (including PSP, PS3 and PS4), and up to the present day with God of War: Ragnarök on PS5, we trace this franchise's storied history, and discuss the various changes - both in-game and behind the scenes - that made this franchise one of the most fascinating epics in all of gaming. Run of Show: 00:10 - Introduction 01:16 - God of War Retrospective First Era (Greek Mythology) God of War (PS2) - 2005 (Dir. David Jaffe) God of War II (PS2) - 2007 (Dir. Cory Barlog & David Jaffe) God of War: Betrayal (Mobile) - 2007 God of War: Chains of Olympus (PSP) - 2008 (Ready at Dawn) God of War Collection (PS3) - 2009 (Remastered Collection of God of War I & II, later ported to Vita in 2014) God of War III (PS3) - 2010 (Dir. Stig Asmussen); Remastered on PS4 in 2015  God of War: Ghost of Sparta (PSP) - 2010 (Ready at Dawn) God of War: Origins Collection (PS3) - 2011 (Remastered Collection of PSP games) God of War Saga - 2012 (Remastered Collection of God of War I, II & III, and digital codes for the PSP games) God of War: Ascension (PS3) - 2013 (Dir. Todd Papy) (Prequel to entire series) Second Era (Norse Mythology) God of War: A Call from the Wilds (text-based game playable through Facebook Messenger) - 2018 God of War (PS4, 2018) (Dir. Cory Barlog) God of War Ragnarök (PS4, PS5) - 2022 (Dir. Eric Williams) 01:34:11 - Closing Thoughts / What's Next on the Podcast

The TBPod
Treatment of Drug Resistant TB

The TBPod

Play Episode Listen Later Dec 1, 2022 34:09


Drug Resistant TB is a growing problem with some exciting advances over the past decade. With the recent Rapid Communication from the WHO and the advent of the B-PALMS regimen, drug resistant TB is a changing and exciting field of tuberculosis around the world.In this episode Professor Greg Fox from the University of Sydney speaks with Dr Jack Callum about the latest changes in the treatment of Drug Resistant TB in light of the WHO Rapid Communication as well as the NIX, ZeNIX and TB Practecal Trials. Professor Fox also addressing the implications for clinical practice and what the future might hold in this ever challenging field of TB.REFERENCES:1) Gegia, Medea, et al. "Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis." The Lancet Infectious Diseases 17.2 (2017): 223-234.2) NIX Study: Conradie, Francesca, et al. "Treatment of highly drug-resistant pulmonary tuberculosis." New England Journal of Medicine382.10 (2020): 893-902.3) ZeNIX Study: Conradie, Francesca, et al. "Bedaquiline–pretomanid–linezolid Regimens for drug-resistant tuberculosis." New England Journal of Medicine 387.9 (2022): 810-823.4) TB Practecal Trial (not yet published but study protocol available):  Berry, Catherine, et al. "TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis." Trials 23.1 (2022): 1-16.5) WHO Guidelines for DR TB Update: World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. No. WHO/UCN/TB/2022.2. World Health Organization, 2022. 6) Commentary on the WHO Update: Migliori, G. B., and S. Tiberi. "WHO drug-resistant TB guidelines 2022: what is new?." The International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease26.7 (2022): 590-591.

Church of Jesus Christ Study Session with Come Follow Me
S4 E308-E309 CFM Nov 14 - Nov 20 Part II-III

Church of Jesus Christ Study Session with Come Follow Me

Play Episode Listen Later Nov 17, 2022 14:53


Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

Because You Watched Starcrash
Back to the Future I, II, & III - Because You Watched Starcrash

Because You Watched Starcrash

Play Episode Listen Later Nov 14, 2022 81:50


Back to the Future(1985), Back to the Future Part II (1989), and Back to the Future Part III (1990) “What are you looking at, Butthead?” In an amazing finale, your time-traveling Distinguished Professors end their journey with the Back to the Future trilogy! Topics discussed include Back to the Future's enduring excellence, the issues with the sequels, Part II's surprisingly weak visual effects (other than the various duplicate actor shots), the Jaws jokes in Part II, Goldie Wilson and Chuck Berry as time-travel causality conundrums, Part I as the perfect script, yet another discussion of David Sirota's Back to Our Future and the 1980s' pop culture connection back to the 1950s, a weird quiz for Clink, the removal of Crispin Glover, runaway product placement, perceptions of time travel shown in the movies, dark theories regarding multiple dead Martys, a bit about how the DeLorean time travels, the badassery of James Tolkan, Mary Steenburgen as the eternal time traveling weirdo's girlfriend, Pat Buttram's brief appearance, Marty's darling atomic cowboy outfit and an unexpected criticism of 1950s nostalgia for the Old West, Marty's ancestor is boning his mom's ancestor (?!), a shoutout to the Wizard and the Bruiser podcast and Marty's “chicken” hubris, future Biff is disturbingly Trump-y, Flea's cameo, Doc would fail Temporal Ethics at Starfleet Academy, our impending date with Howard the Duck, the weird choice of ZZ Top to be the soundtrack pop song anchor for Part III, the great Alan Silvestri score, a callback to Action Replayy, incest comes up yet again, the two tension-building clocks in Part I and the color-coded logs in Part III, the radically different landscape for Part III, our ideal retrofutures, a gold star for Marty for not murdering Mad Dog Tannen, and making like a tree and getting out of here. Follow us on Facebook! Because You Watched Starcrash Music credits: "Laser Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/because-you-watched/support

Church of Jesus Christ Study Session with Come Follow Me
S4 E301-E302 CFM Nov 7 - Nov 13 Part II-III

Church of Jesus Christ Study Session with Come Follow Me

Play Episode Listen Later Nov 10, 2022 12:33


Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

El FreakShow
De Profundis Vox : Vol II - III: Guillermo del Toro

El FreakShow

Play Episode Listen Later Oct 24, 2022 83:59


Donde hablamos de uno de los mexicanos más creativos y que sabe como causar fascinación con sus monstruos: Guillermo Del Toro.

LOCOMOTIVE BREATH
KISS ALIVE I.II.III.IV

LOCOMOTIVE BREATH

Play Episode Listen Later Oct 12, 2022 119:22


Locomotive Breath Podcast 12.10.22KISS ALIVE I.II.III.IV Rivivi insieme a Noi le Travolgenti emozioni di un Live dei KISS con i Loro 4 Live Album più rappresentativi.

Church of Jesus Christ Study Session with Come Follow Me
S4 E265-E266 CFM Oct 3 - Oct 9 Part II-III

Church of Jesus Christ Study Session with Come Follow Me

Play Episode Listen Later Oct 6, 2022 19:44


Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

ThePrint
ThePrintPod: छोटे शहरों के युवाओं के लिए आसान लोन से जगी उम्मीदें, एफोर्डेबल देशों में पढ़ने का सपना हो रह

ThePrint

Play Episode Listen Later Sep 28, 2022 8:30


शिक्षा सलाहकारों और वित्तीय संस्थानों का दावा है कि टियर II और III के शहरों में रहने वाले छात्रों की विदेशों में शिक्षा के प्रति दिलचस्पी बढ़ी है. इन छात्रों का कहना है कि विदेशी डिग्रियां उनके अच्छे भविष्य के लिए मददगार साबित होंगी.  

Modo 7 Podcast
Modo 7 Podcast 34 - Mega Man I, II, III

Modo 7 Podcast

Play Episode Listen Later Sep 28, 2022 101:11


Este episodio ha sido todo un parto, pero finalmente está aquí. Hablamos a profundidad sobre las tres primeras entregas de uno de los personajes más queridos que haya creado por Capcom.

Bounty Hunt: A Star Wars Podcast by Youtini
Ep. 56: Andor - Episodes I, II, III

Bounty Hunt: A Star Wars Podcast by Youtini

Play Episode Listen Later Sep 27, 2022 93:23


Star Wars: Andor has arrived on Disney+, and we'll be discussing the first three episodes, our opinions of the characters, and what sets it apart from past Star Wars projects. ▶StarWars: Andor - Special Look (http://StarWars.com (StarWars.com)) | https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbmZrTVRqYXR3T2dzYmttNHZ2cDJ5RFM0eEl4UXxBQ3Jtc0tta2p1cGFoTUxjcUJTSEIxYlBCNGRGTGpid2EtTUZyQ1pVN2tuN0d5Y3B3ZURWelhqNUxQV0hLUHZrTlJkb01HTHZrN2twUFFLT0tKWGVGTmRqeXJxWXBhUFJZRlFDWU5tWjRlTnlWdnFLdC15WkdCQQ&q=https%3A%2F%2Ftinyurl.com%2Fyc5bnw6j&v=DIRU4Pf8ihc (https://tinyurl.com/yc5bnw6j) ▶Cassian Andor 101 - The Story of a Rebel (http://StarWars.com (StarWars.com)) | https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbFJ5X1ZnWU5qczRTV1FmTnlhc2xZSTM2NVFnd3xBQ3Jtc0ttZHJ0em5pZnNKWkhvaWFYYmdQZXFydl93OTBxTkJqeDBzcGVVd0lIMXJHd0I2NmVjM2dWcmhBMHB2Z0RZQUlZSkZrSE1RTkFoYThyTkNvSEJKbnFkRmRDdFVxWTlreXZEMlNZd0dWRXlGTmRhQkN6SQ&q=https%3A%2F%2Ftinyurl.com%2F3ktvwpey&v=DIRU4Pf8ihc (https://tinyurl.com/3ktvwpey) ▶The Youtini Book Review System | https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbTBLX1VyNHVVLXVfN280SWlMZjlDOEp6MWJJZ3xBQ3Jtc0trQzNyaU91MUNmMVlGSXZDU0FJTXU3WF8xekxueVp1a05qempBYUROTlAwZksydUhiQzE2UFA4WkFmekREa3BKT2QyeF81cWRtU1JFbzFIbHhKZ1BXTDZfSkZGU1FOSG4xRFd4bjZOVFdmQll3eWliUQ&q=https%3A%2F%2Ftinyurl.com%2F2p857edd&v=DIRU4Pf8ihc (https://tinyurl.com/2p857edd) ▶New Book & Comic Releases on http://Youtini.com (Youtini.com) | https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbjl5Qk9sY3ljOGRtRmhKMi1BU21PYVp6UEhSZ3xBQ3Jtc0tsLWQ3Y0s2Rkh0TnlpNk1UeUk1MS1jSHFTd2FWR2xlb24xQk1HMU1WS24zSEhXMHhJRFFMblQzanJFdWZuSnZhYWJleTNpb1pqQ2x6Zm9oUS0tSjlReTlnTDROcWRGZ3RmTFpNbWQzQVBOdzYyeW5OMA&q=https%3A%2F%2Ftinyurl.com%2F4bnhp8du&v=DIRU4Pf8ihc (https://tinyurl.com/4bnhp8du) ▶Complete Star Wars Timeline | https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbS1ocFNZckdRNElpWGJBRE42Yk5xUXZ4c19Cd3xBQ3Jtc0trbmRRcllZMDF2VWtFbmpfcnRlTkhrUjM5X0lWNFRUeXNzSHVKLWNuRE5JRzRMYll3eUQtSlhNUUdmanBaUGVyMlZ3cHdqbjAwajJadDF4aHo3Z3ZCWFBRMzhZMF9jQWhxZFhueVJGSjk0VW5hSEJQcw&q=https%3A%2F%2Ftinyurl.com%2Fyznkb8w7&v=DIRU4Pf8ihc (https://tinyurl.com/yznkb8w7) JOIN OUR COMMUNITY ▶ WEBSITE https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbW9oMEZLZ0hGc01RNVFZQnYzdnlJLVEtZVNlQXxBQ3Jtc0ttUUZlOWZ3T2xVbWVoVVVuMW1NN1puZWZ6OWZVeTFfMXo1ZDlraUhyWE4tTHJPaHN3UnJCcjlxbXhsam9WdTBrUV9HbzZXNzZpaWI2RkstS242ckdSMkNLSWpWMXpIS3pGNHYxYVdwU0drTjgwMURVVQ&q=https%3A%2F%2Fwww.youtini.com%2F&v=DIRU4Pf8ihc (https://www.youtini.com) ▶ DISCORD https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbUExSXZsN1F6Sl9kTmlzYmpzd1lZU1JYd3ZWUXxBQ3Jtc0tsS201MTR2NmtDTjQ4cXdCVUJTaXVBeGJVbnB3TmZWd0k1MFdZWFNicWdodi1qeWNjamtQQ21qdUVzVVVISFh2Nm5yb2I2Z0xfRmJpQ3Rzdi1kR1lOMEUwUkJZVWtRZl83YXhLUU5GNUdaZ282TktkOA&q=https%3A%2F%2Fwww.youtini.com%2Fdiscord&v=DIRU4Pf8ihc (https://www.youtini.com/discord) ▶ TWITTER https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbjBnTmhhVnl5QW9ZeldoYUl4dVk3cnJseXhIUXxBQ3Jtc0tsU1FPYXB1ZFdKY0IyLUVmaUFqUVFsaWFReXFJMzllZ2V6YmZpODREVFd0bnJWZDVtQ18wdDNSNkRvX3MxWlpWVDVTbDgwWlhCRS1haVRlVjhfYklaajQtMzRQdzlTZU1zSWJMZjRnUEQwdnpZWmpNWQ&q=https%3A%2F%2Ftwitter.com%2Fyoutini_us&v=DIRU4Pf8ihc (https://twitter.com/youtini_us) ▶ INSTAGRAM https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbHJWY0lPZlk3MnNXWmdrejlfZ2sxck9DVE5HUXxBQ3Jtc0tsTlExcmZyV25KLTEzR1VXTWUydUhYaHZxZmRraTRHQXZ2Q2N3X0F5Q1lndzVaVzZock9MeUNNMVNGT0FvT1gwQ1g3TVFMZnQ4NzNNVE9mNzEwdndlX0Q1X21HbE9GZ0hwVEVsOTU0V2EtREtGeXZvUQ&q=https%3A%2F%2Fwww.instagram.com%2Fyoutini_us%2F%3Fhl%3Den&v=DIRU4Pf8ihc (https://www.instagram.com/youtini_us/...) ▶ FACEBOOK...

Haunted History Chronicles
Ghosts of The White House

Haunted History Chronicles

Play Episode Listen Later Sep 16, 2022 14:04


In today's episode we explore some of the history and hauntings from within The White House. From ghostly knocks, to apparitions of a soldier walking the grounds and a First Lady completing her laundry The White House has many ghostly stories and encounters to share.... Thank you for listening. If you want to get your hands on The Feminine Macabre Volume I, II III or IV then make sure to take a look at https://spookeats.com/femininemacabre/ or via Amazon. You can explore my chapter titled, 'In Search of the Medieval' in Volume III. If you wish to support the Haunted History Chronicles Podcast then please click on the Patreon link. https://www.patreon.com/Haunted_History_Chronicles Please use the links below or on the website to keep in touch via our social media pages : to ask questions and review other content linked to this episode. Facebook: https://m.facebook.com/HauntedHistoryChronicles/?ref=bookmarks Twitter: https://twitter.com/hauntedhistory4 Instagram: instagram.com/haunted_history_chronicles Website: https://www.podpage.com/haunted-history-chronicles/ --- Send in a voice message: https://anchor.fm/hauntedchronicles/message

Cancer.Net Podcasts
2022 Research Round Up: Head and Neck Cancer, Brain Tumors, and Health Equity

Cancer.Net Podcasts

Play Episode Listen Later Aug 25, 2022 29:04


ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. In the Research Round Up series, ASCO experts and members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today's episode, our guests will discuss new research in head and neck cancer, brain tumors, and health equity that was presented at the 2022 ASCO Annual Meeting, held June 3-7 in Chicago, Illinois. First, Dr. Cristina Rodriguez will discuss 2 studies on new treatment options for locally advanced head and neck cancer. Dr. Rodriguez is a medical oncologist at Seattle Cancer Care Alliance, an Associate Professor in the Division of Medical Oncology at the University of Washington, and an Associate Member for solid tumor clinical research at the Fred Hutchinson Cancer Research Center. She is also the Cancer.Net Associate Editor for Head and Neck Cancers. You can view Dr. Rodriguez's disclosures at Cancer.Net. Dr. Rodriguez: Hello. My name is Christina Rodriguez. I'm a medical oncologist with a clinical and research focus on head and neck cancer. And today I'm going to discuss research on head and neck cancer that was presented at the most recent 2022 ASCO Annual Meeting. I don't have any relationship to disclose that pertains to the research that I will talk about today. I'd like to discuss 2 abstracts that I thought were practice changing or practice affirming that really addresses some of the key questions that patients and doctors like me have about the treatment of patients with head and neck cancer. So, as you know, most patients with head and neck cancer present with typically locally advanced disease, and most head and neck cancer patients are treated with the intent of curing them most of the time with the use of radiation either as the main treatment or after surgery. And many clinical trials have shown that when we add a chemotherapy called cisplatin to radiation, we improve curative outcomes for patients. But the first abstract that I will talk about, abstract 6003, asks the question "What do we do for patients who are not candidates for cisplatin chemotherapy?" And we know that a significant proportion of our patients will have other medical problems that could make it difficult for us to give chemotherapy and often will result in complications or more toxicity or in side effects for patients. This clinical trial was carried out in India, and it compared radiation alone for patients with head and neck cancer versus radiation given with a non-cisplatin chemotherapy called docetaxel. What's unique about this clinical trial is that it's specifically focused on patients who were not candidates for cisplatin chemotherapy, something that really hasn't been done for this population. Interestingly enough, they found that when we give docetaxel with radiation in these patients, we find that they do better, they live longer, and they feel better based on quality-of-life questionnaires. So I will say that this study, abstract 6003, tells us that even in patients who are not candidates for cisplatin to be given with radiation, there is an alternative treatment that we can use, such as docetaxel given with radiation, that might still improve patient's cure rates for their head and neck cancer. The second study that I think was another interesting study was a clinical trial that asked the question, "Can we give cisplatin in an alternative manner for patients who are undergoing definitive radiation treatment as their main treatment for head and neck cancer?" Like I mentioned, the clinical trials that led to the use of chemoradiation as a standard use cisplatin given in larger doses every 3 weeks, but there's been concern about how well that approach is tolerated by patients. So this particular clinical trial compared patients receiving radiation as curative intense therapy for head and neck cancer with either the cisplatin given every  3 weeks or the cisplatin given at a lower dose once a week. It's important to know that this trial was done in India, where the population is pretty different from what we see in the United States. These are mostly patients who have HPV-negative cancers, mostly cancers acquired through exposures like tobacco and alcohol. And what they found was that these 2 groups of patients had very similar outcomes. In other words, there didn't seem to be a reduction in the rates of cure when we give chemotherapy every week versus every 3 weeks. And interestingly enough, it looked like from a toxicity or side effect standpoint, the every week seems to be a little bit better tolerated. Patients who got the treatment every 3 weeks also had less need for hospitalization or IV fluids and less utilization of health care resources. I think this is a very interesting finding because it really provides us with what we call high-level data that the weekly administration can work. I think it's important to recognize that the population that it studied for this particular clinical trial really was more an HPV-negative population. That's important to know because the standards for HPV-positive head and neck cancer are generated from larger trials that use cisplatin every 3 weeks. But we are continuing to study this question, and there's actually a large NRG study, HN009, that is asking that question both for the HPV- positive and HPV- negative population. So we are, I think, making strides in terms of asking the questions that allow our patients not only to receive treatment that is highly efficacious but also that limits side effects and toxicity. I will also mention that these trials were completed during the COVID-19 pandemic, which tells you that the dedication of these researchers to complete something like this in such a challenging time is to be commended. That's all I have to say, and thank you for listening to this brief summary of new research in head and neck cancer from the ASCO 2022 Annual Meeting. ASCO: Thank you, Dr. Rodriguez. Next, Dr. Glenn Lesser will discuss 3 studies that looked at new treatments for different types of brain tumors. Dr. Lesser is the inaugural Louise McMichael Miracle Professor and Associate Chief in the section on Hematology and Oncology in the Department of Internal Medicine at Wake Forest Health. He is also the Cancer.Net Associate Editor for Central Nervous System Tumors. You can view Dr. Lesser's disclosures at Cancer.Net.   Dr. Lesser: Hello. My name is Glenn Lesser, and I'm a professor of medical oncology and the director of medical neuro-oncology at the Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, North Carolina. I'm also the editor of the brain tumor section for ASCO's Cancer.Net. And today, I would like to briefly discuss several clinically relevant research studies involving patients with brain tumors that were presented at this year's ASCO Scientific Program. Of note, I have no disclosures or relationships relevant to the abstracts I'll be discussing today. The first presentation to talk about is a late-breaking abstract presented by Dr. Eric Bouffet, who described the results of a phase II trial of 2 targeted anticancer agents, dabrafenib and trametinib, in pediatric patients with a kind of brain tumor called a low-grade glioma, which harbored something called a BRAF V600E mutation in their tumor DNA. By way of background, gliomas account for about 45% of all pediatric brain tumors, and the majority of these gliomas are low-grade, which include World Health Organization grade 1 and 2 tumors. Common types of pediatric low-grade gliomas include pilocytic astrocytomas, gangliogliomas, and low-grade gliomas that are not otherwise specified. Now, mutations in the BRAF gene are common in certain kinds of cancers, particularly melanoma, and novel oral targeted therapies have been developed to effectively treat these tumors by targeting this mutant BRAF gene. A particular mutation in this gene called a V600E mutation occurs in about 15% to 20% of pediatric low-grade gliomas. The presence of this mutation is thought to lead to an increased risk of progression to a higher grade or a more malignant glioma in these patients, and these mutations in their tumors also predict a less favorable response to chemotherapy. In adults, recent studies in patients with malignant gliomas, papillary craniopharyngiomas, and melanomas containing V600E mutations have shown excellent results, with 1one of several similar 2-drug combinations that target both the V600E mutation and a second pathway that cells use to escape from this BRAF blockade. Now, early pediatric data suggested that one of these pairs of drugs, the combination of dabrafenib and trametinib, was safe and tolerable and had the ability to effectively treat patients whose tumors had the V600E mutation. So with that as background, this study was started and enrolled patients from 12 months to 18 years of age who had a low-grade glioma that contained a BRAF V600E mutation. And it randomized them to receive either the combination of dabrafenib and trametinib, or an older, standard cytotoxic chemotherapy regimen consisting of carboplatin and vincristine. Importantly, these patients were newly diagnosed, and this was the first systemic treatment they got, following their surgery or biopsy. 110 patients were enrolled, with 73 given the new targeted therapy combination and 37 receiving the standard combination. The most common types of tumors that the patients enrolled on this study had included pilocytic astrocytoma, ganglioglioma, and low-grade glioma. The results of this trial were that the patients who received the newer combination, targeted treatment of dabrafenib and trametinib, did substantially better than those who received standard, older cytotoxic chemotherapy. Their overall response rate - that's defined as a complete or partial disappearance of the tumor on MRI scan - was 47% versus 11% in the control arm. When patients who had stable disease by MRI were included, 86% of those on the new combination versus 46% of those patients treated with the older chemotherapy had the so-called best clinical response. Now, a large number of patients responding to dabrafenib and trametinib, remain on treatment and are receiving these drugs with an ongoing imaging and clinical response at the time of this report. Patients receiving the new combination had a median or average progression-free survival of 20 months versus about 7.4 months with the older, standard chemotherapy. The investigators conducting this study also had patients fill out a variety of questionnaires to assess their quality of life while on treatment. Once again, the patients who received dabrafenib and trametinib, on average, experienced an improved quality of life in contrast to those on standard chemo who, on average, had a worse quality of life. The new treatment was also well-tolerated with fewer serious adverse events or side effects when compared with standard chemotherapy. And these side effects were no different than what has been seen in patients without brain tumors who have been treated with this combination, including fevers, headaches, fatigue, skin changes, and lower blood counts. The authors appropriately suggested that these findings demonstrate the importance of molecular testing of these pediatric low-grade glioma tumors at the time of diagnosis and that this combination of dabrafenib and trametinib is a new potential standard of care in those patients who have the BRAF V600E mutant, low-grade tumors. Of note, liquid formulations of these drugs have been developed for those pediatric patients who are unable to swallow capsules or tablets. The second presentation at ASCO highlighted the continued importance of prospective randomized clinical trials in patients with malignant brain tumors. Dr. Jann Sarkaria from the Mayo Clinic presented the long-awaited results of the Alliance for Clinical Trials in Oncology cooperative group phase II/III study of a PARP inhibitor or placebo added to standard temozolomide and radiation in adult patients with newly- diagnosed glioblastoma, and in addition, glioblastomas that had specific molecular finding called MGMT promoter methylation. This change to the DNA of the tumors prevents the MGMT DNA repair enzyme from being made in the tumors and leads to a better outcome with temozolomide treatment. Some very elegant laboratory science had suggested that adding a type of drug called a PARP inhibitor, which also causes defects in DNA repair, could lead to improved killing of glioblastoma tumor cells. So patients with newly- diagnosed glioblastomas, which had MGMT promoter methylation on genomic analysis, were enrolled on this study between December of 2014 and October of 2018. The study was conducted in 2 phases separated by a pre-planned pause after the first group of patients were enrolled, which was the phase II part of the study. This was done in order to allow a preliminary analysis of the outcomes of the treatment arms to make sure that there was a signal of activity that justified moving on to test this treatment in a larger number of patients, the so-called phase III part of the trial. This trial design hopes to minimize the number of patients treated with an inactive drug and save years of drug development time by avoiding large trials that go on for a long time with what turns out to be ineffective drugs. For this trial, 447 patients were eventually treated on this trial. Despite the convincing laboratory evidence and early, promising clinical results that led to the trial moving to the second or phase III portion, the final results showed no statistically significant difference in progression-free or overall survival between the 2 arms, that is, those treated with a PARP inhibitor, and those treated with placebo. I personally was very excited about this study and had hoped that the long wait to hear the results indicated that something good was happening. In addition, several of my patients who were treated on the study did exceedingly well, so I, incorrectly, it turns out, expected positive results from the trial. These negative results are a stark reminder of why we spend lots of time and money and energy performing well-designed clinical trials to determine appropriate treatment strategies for our patients, rather than relying on expert opinion or 1 institution's published experience. This approach turns out to be the best way to fairly test treatment strategies and establish new therapeutic approaches which are truly effective. A final, interesting abstract that was presented at a poster discussion session at ASCO was from the group with the University of Pennsylvania in Philadelphia, and it dealt with the risk of bleeding in patients with brain tumors who had blood clots and were then treated with a newer class of blood thinners or anticoagulants called direct oral anticoagulants, or DOACs for short. It's been known for over 100 years that a variety of types of cancer cause patients to be hypercoagulable, that is, to be predisposed to developing blood clots throughout the venous system. Patients with malignant brain tumors have the highest incidence of all tumors of developing blood clots, which typically occur in the legs, called deep venous thrombosis or DVTs, or in the lungs, called pulmonary emboli or PEs. These clots can lead to a variety of severe and debilitating symptoms, including leg pain, swelling, shortness of breath, heart strain, and even death. For the past 2 to 3 decades, affected patients have typically been treated with a class of medications called low-molecular-weight heparins, which need to be injected under the skin once or twice daily. Over the past decade, a new class of oral anticoagulants called DOACs have generally replaced low-molecular-weight heparins as the primary method of treatment for patients with and without cancer who develop venous blood clots because of their safety, ease of administration, and a lack of requirement for regular blood tests or monitoring. However, little, if any, data has been available to determine the safety of these agents in patients with brain tumors and blood clots, a situation where bleeding into the brain or the brain tumor as a side effect of the anticoagulant could be catastrophic. In fact, this potential risk led to the exclusion of patients with brain tumors from several of the large trials which established the safety of the DOACs. Despite the absence of evidence, the DOACs are now pretty broadly used in brain tumor patients for the reasons described above. So this abstract described a cohort of patients with glioblastoma who developed venous blood clots between 2014 and 2021 while under treatment at Penn. The authors reviewed the medical record to determine the relative efficacy or effectiveness and the toxicity or side effects experienced by patients treated with the low-molecular-weight heparins and with the DOACs, including the rates of bleeding into the brain or the brain tumor. 121 patients were identified who fit these criteria, and the cumulative incidence of clinically significant intracranial hemorrhage, that is, bleeding into the brain or the brain tumor, by 30 days after starting the drugs, was minimal and similar in the 2 groups. When measured at 6 months, 24% of the patients in the low-molecular-weight heparin group had developed intracranial bleeding, and 4 of those patients had died from this bleeding, while none of the 32 patients in the DOAC group experienced this complication. Thus, these investigators felt that their data suggested that there was a lower incidence of clinically important intracranial hemorrhage or bleeding in patients with glioblastoma and venous blood clots who were treated with DOACs as compared to low-molecular-weight heparin. They went on to suggest that the use of DOACs was a safe alternative in patients with glioblastoma. Now clearly, either a prospective trial, a larger trial, or additional retrospective evaluations with a larger number of patients are needed to prove the safety of this approach. But this data is pretty comforting, as the use of these agents is now widespread in patients with high-grade gliomas. The ease of administration of a pill once or twice a day, as compared with potentially lifelong injections once or twice a day, is a major quality of life advantage for our patients. Thank you for listening to this brief summary of new research in neuro-oncology from the 2022 ASCO Annual Meeting. ASCO: Thank you, Dr. Lesser. Finally, Dr. Manali Patel discusses new research focused on reducing disparities in cancer care. Dr. Patel is a medical oncologist and Assistant Professor of Medicine at Stanford University. She is also the Cancer.Net Associate Editor for Health Equity. You can view Dr. Patel's disclosures at Cancer.Net. Dr. Patel: Today I have the privilege of discussing several really exciting research abstracts that were presented at the 2022 ASCO Annual Meeting. My name is Manali Patel. I'm a thoracic oncologist, meaning I take care of patients and try to provide good care delivery for patients with lung cancer. And I also am a researcher focused on health equity. I have no relevant disclosures for any of the studies that I will be presenting today with the exception of one that I was leading. And there were several wonderful abstracts that were presented on describing disparities and the ongoing state of disparities continuing within cancer care delivery. What I was particularly struck by were many of the abstracts that I'm presenting this morning and this podcast that really focus on what we can do as a nation and what we can do individually in our clinics to try to move towards action to overcoming these inequities. The first abstract I want to present was looking at how the Affordable Care Act and changes in the Affordable Care Act led to differences in mortality or deaths by race and ethnicity following the enactment in California. And this particular study looked at greater than 150,000 people who were diagnosed with breast cancer, colorectal cancer, and cervical cancer. And they evaluated death rates from these cancers both before and after the implementation of the Affordable Care Act. And what they found was that the cancer death rates for everyone was much lower after the Affordable Care Act was passed, but specifically for individuals who had self-identified as Hispanic ethnicity, who also identified as Black and who identified as White. And so what this abstract showed me was that at a larger level and a macro level, our policies that are enforced at the national level really do play a role in terms of how we can overcome disparities in cancer. Our group, as I mentioned before, has worked on really trying to integrate community health workers into care. So this abstract paired with local union organizations in Chicago and in Atlantic City to try to help individuals who self-identified as having been from families that were from low-income households and racial and ethnic minorities to communicate their goals and their preferences for care and to also better their relationships with their clinicians as well as to describe their symptoms. And what we found in this randomized trial was that for individuals who received this community health advocate who helped them to better engage with their clinician and who also helped them to describe the symptoms that they were experiencing as well as receive community resources such as food boxes if they were food insecure or be connected to household agencies if they were having difficulties with housing, we found a significant improvement in quality of life, but we also found reductions in the use of the hospital unnecessarily. We also found that this translated into reductions in total cost of care, thereby reducing the amount of out-of-pocket costs these individuals were spending on their cancer care. One of the other abstracts that I thought really was reflective of the many different ways that we can move towards action was an abstract which looked at during the pandemic, trying to reduce the number of times people need to come in for mammograms, their biopsies, and then any further testing that they needed after their biopsy. And this particular study evaluated what was called a same-day biopsy service, which layered on a same-day mammogram reading program. So at this particular institution, they had already implemented when you came in to get your mammogram as a woman or a man, you would have a read on the same day. So you did not have to wait to find out what your results were. And what they did further to push better care was that they layered on on that same day you could get your biopsy. So almost a one-stop shop. And what they found was that for everyone, regardless of race and ethnicity, the time to biopsies decreased by almost half. And the median days, for example, from an abnormal mammogram to obtaining a biopsy, meaning a sample of that tissue, that it decreased from 10 days median to 5 days. And particular patient populations did much better. And so they were able to show that when you do interventions that move the care to provide better care for everyone, everyone benefits, but particularly our patient populations who identify as racial and ethnic minorities who were more likely to experience delays in care, they also received some benefit from this intervention. The last study I want to highlight is work which looked at how to improve specialized services for people who would otherwise not receive those. And this particular study looked at stem cell transplantation for people with blood cancers. And what they found was that these services are often only offered in very tertiary centers, so places that may not be as accessible, large institutions that a lot of people may not have access to receiving care. So what they did was they partnered with this large academic institution so that they could build a pathway for individuals who would otherwise not get stem cell transplantation so that they could have access to those services. And it was really a multipronged approach where they not only educated the clinicians in the community practice about the effort, but they also educated the institution-level clinicians about the effort. They also provided shared medical records, which oftentimes in practice, we don't share our medical records with other clinics. And what they were able to do was to convince these clinics and the institution, let's share the medical records so that then you can have access to seeing what's happening for patients that are diagnosed in the community. And then that way we can both document, we can both have access in the community as well as in the institution where they're receiving the specialized service so that there's better communication. They also provided a navigator for each patient that would help each patient to identify any sort of barriers that they may experience to receiving stem cell transplantation. And then they offered telemedicine, which allowed for individuals to receive specialized services in the comforts of their own home without having to travel after the stem cell transplantation had occurred. And what they found was that usually in the institution, most individuals were more affluent. So they had higher levels of socioeconomic status. But after the intervention, individuals that were referred from this community clinic made it such that the affluence really decreased so that it was showing that people who wouldn't otherwise have access, who had identified as having low income, were now able to receive those services and had been receiving transplantation. I think that these studies really do move us towards a new paradigm of taking action on the many disparities that we know continue to happen. I really appreciate you all for listening to this brief summary of the new research on health equity from the 2022 ASCO Annual Meeting, and I hope to see you next year. ASCO: Thank you, Dr. Patel. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Les indispensables - Europe 1
«McCartney I / II / III» : Paul McCartney signe son retour dans les bacs

Les indispensables - Europe 1

Play Episode Listen Later Aug 5, 2022 7:02


Chaque jour, deux chroniqueurs présentent les infos indispensables à connaître en matière de culture : les dernières actus musique, les sorties littéraires ou cinéma, les nouvelles pièces de théâtre et les séries à ne pas manquer... C'est ici !

This We Confess
33 Of the Last Judgement II-III - This We Confess Podcast

This We Confess

Play Episode Listen Later Jul 25, 2022 27:56


What is the day of judgement for? When will it be?

Edengrove Presbyterian Church
33 Of the Last Judgement II-III - This We Confess Podcast

Edengrove Presbyterian Church

Play Episode Listen Later Jul 25, 2022 27:56


What is the day of judgement for? When will it be?

Que dit la Bible ?
HE5 #4 – Constantinople II - III Et Nicée II

Que dit la Bible ?

Play Episode Listen Later Jul 22, 2022 37:10


HE5 #4 – Constantinople II - III Et Nicée II by LBC

Church of Jesus Christ Study Session with Come Follow Me
S4 E195-196 CFM Jul 18 - Jul 24 Part II-III

Church of Jesus Christ Study Session with Come Follow Me

Play Episode Listen Later Jul 21, 2022 20:15


Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

The Kinocast
Episode 57: Dinosauws (Jurassic Park I, II, III)

The Kinocast

Play Episode Listen Later Jul 8, 2022 62:21


Sorry for being inactive I've been too busy to edit but today I am dropping three episodes.Our Patreon

Church of Jesus Christ Study Session with Come Follow Me
S4 E176-E177 CFM Jun 27 - Jul 3 Part II-III

Church of Jesus Christ Study Session with Come Follow Me

Play Episode Listen Later Jun 30, 2022 20:51


Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

ScienceLink
Congreso Anual de la Sociedad Americana de Oncología Clínica 2022: Tumores del SNC

ScienceLink

Play Episode Listen Later Jun 28, 2022 14:28


El Dr. Raúl Rogelio Trejo Rosales, oncólogo médico adscrito al Centro Médico Nacional “Siglo XXI”, IMSS en la Ciudad de México, México, junto con el Dr. Idelfonso Roberto De La Peña Valle, oncólogo médico adscrito al Instituto Nacional de Ciencias Médicas Salvador Zubirán en la Ciudad de México, México, nos comentan lo más destacado sobre tumores sistema nervioso central presentado durante el Congreso Anual de la Asociación Americana de Oncología Clínica 2022. Cáncer de cerebro: Abstract 2032: Revisión retrospectiva de gráficos para evaluar la proporción de pacientes con cáncer de cerebro que recibieron tratamiento dirigido vs. terapia estándar después de la secuenciación. Los pacientes se estratificaron en 1 de 3 categorías: astrocitoma, oligodendroglioma u otros subtipos raros (incluidos meningioma, ependimoma, ganglioma, xantoastrocitoma pleomórfico, tumores rabdoides teratoides atípicos, tumores glioneuronales y linfomas del SNC). Diagnóstico: Abstract e14022: Impacto de la secuenciación de próxima generación (NGS por sus siglas en inglés) en el diagnóstico de gliomas según la clasificación WHO-2016 y WHO-2021 en la práctica clínica habitual. Abstract e14009: Patrones de tratamiento y resultados de pacientes con glioma de alto grado durante la pandemia de COVID-19. Abstract 2055: Evaluó la asociación de mielosupresión (neutropenia, trombocitopenia, anemia, linfopenia) durante la quimiorradioterapia con temozolomida solo o en combinación con agentes experimentales con supervivencia libre de progresión (SLP) o supervivencia global (SG) en 2073 pacientes con glioblastoma recién diagnosticado inscritos en 5 estudios clínicos: CENTRIC, CORE, EORTC 26082, AVAglio y EORTC 26981. Abstract 2052: Se contactó a 166 centros oncológicos de todo el mundo para recuperar datos de pacientes con tumores del SNC con TRK. Los datos extraídos incluyeron demografía, histopatología, fusión del gen TRK, modalidades de tratamiento y resultados. Tumores SNC: NAVIGATE: Estudio fase II que evalúa larotrectinib en pacientes adultos y pediátricos con tumores NTRK. Su objetivo primerio es evaluar la eficacia en tumores sólidos y el secundario es evaluar eficacia y seguridad. Glioblastoma: Abstract 2067: Estudio retrospectivo realizado en el Hospital de Oncología, Centro Médico Nacional Siglo XXI. Se incluyeron pacientes histológicamente confirmados con gliobastoma tratados en un período de enero de 2015 a enero 2019. A los cuales se les sometió a cirugía seguida de temozolomida (TMZ) administrada simultáneamente con radioterapia (RT) y seguido de TMZ adyuvante vs. RT sola. ChiCTR2000028957: Estudio fase II, abierto, de un solo brazo que evaluó a pacientes con GBM confirmado histológicamente con progresión definida después de la cirugía seguida de RT y quimioterapia (QT) con temozolomida fueron elegibles para la inclusión. NCT03522298: Estudio fase II, abierto, que evaluó la seguridad, la farmacocinética y la eficacia de paxalisib en pacientes con GBM caracterizado por el estado del promotor de O6-metilguanina-metiltransferasa no metilado después de la resección quirúrgica y la terapia de quimiorradiación concomitante estándar con temozolomida. NCT03139916: Estudio fase II, abierto que evalúa bavituximab con radiación y temozolomida en pacientes con glioblastoma recién diagnosticado. NCT02152982: Estudio fase II/III, aleatorizado, doble ciego que evaluó veliparib o placebo en combinación con temozolomida adyuvante en pacientes con GBM recién diagnosticado con MGMT promotor de hipermetilación.

Not All Podcasts Wear Capes
NAPWC - Issue 56 - Obi Wan Kenobi: Episodes I, II, III

Not All Podcasts Wear Capes

Play Episode Listen Later Jun 28, 2022 86:39


Hello there! Obi Wan Kenobi may have ended so what better time to drop our podcast talking episode 1, 2, and 3! May the force be with you!

The Intergalactic Peace Coalition Podcast | IPC
#349: Star Wars Celebration Recap & Obi-Wan Kenobi Parts I, II & III

The Intergalactic Peace Coalition Podcast | IPC

Play Episode Listen Later Jun 14, 2022 162:28


Ben is back from 'Star Wars Celebration Anaheim 2022' to recap all the exciting Star Wars reveals and he's joined by Zach and producer Shawn to also discuss Parts I, II & III of 'Obi-Wan Kenobi'.   Watch This Episode On YouTube: https://bit.ly/3NTMQ4s Find All Our Links Here: https://linktr.ee/IPCPodcast

Plenary Session
2.66 PD1 Ab for MSI H Stage II/ III Rectal Cancer; A 100% CR rate??

Plenary Session

Play Episode Listen Later Jun 8, 2022 24:12


Are the results from Luis Diaz as good as touted. What trial should they do going forward? A 100% CR rate in Stage II and III rectal cancer??

ScienceLink
Highlights Día 4 Congreso Anual ASCO 2022

ScienceLink

Play Episode Listen Later Jun 7, 2022 25:49


El Dr. David José Heredia Vázquez, oncólogo médico adscrito al Departamento de Tumores Torácicos del Instituto Nacional de Cancerología, en la Ciudad de México, México, nos comenta en este podcast sobre los highlights del día 4 del Congreso Anual de la Sociedad Americana de Oncología Clínica 2022. Cáncer de ovario: ATHENA-MONO: Estudio fase III, aleatorizado y doble ciego, que evaluó rucaparib en monoterapia vs. placebo como tratamiento de mantenimiento después de la respuesta a la quimioterapia (QT) de 1L basada en platino en pacientes con cáncer de ovario. Cáncer colorrectal: OPTICAL: Estudio fase III, multicéntrico y aleatorizado, que evaluó la QT perioperatoria con mFOLFOX6 o CAPOX vs. el estándar de tratamiento, en pacientes con cáncer de colon localmente avanzado. IMPROVE: Estudio fase II, prospectivo, aleatorizado, no comparativo, abierto y multicéntrico, que evaluó panitumumab intermitente o continuo + FOLFIRI como tratamiento de 1L en pacientes con cáncer colorrectal metastásico, irresecable, sin tratamiento previo, RAS/BRAF w/t. TRIPLETE: Estudio fase III, aleatorizado, de etiqueta abierta, y prospectivo, que evaluó mFOLFOXIRI + panitumumab vs. mFOLFOX6 + panitumumab, como tratamiento inicial en pacientes con cáncer colorrectal metastásico RAS/BRAF w/t no resecable. Sistema Nervioso Central: Alliance A071102: Estudio fase II/III, aleatorizado, que evaluó veliparib o placebo + temozolomida adyuvante en pacientes con glioblastoma recién diagnosticado con hipermetilación del promotor del gen MGMT. Cáncer de pulmón: BTCRC LUN 16-081: Análisis del ADN tumoral circulante del estudio fase II, aleatorizado, que evaluó la consolidación de nivolumab + ipilimumab vs. nivolumab solo, después de QT + radioterapia concurrente en pacientes con cáncer de pulmón de células no pequeñas en estadio III irresecable. Fecha de grabación: 06 de junio de 2022. Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

Ahch-To Radio
Obi-Wan Kenobi: Parts I, II, & III Discussion with Nicky Kumar - Ahch-To Radio

Ahch-To Radio

Play Episode Listen Later Jun 7, 2022 152:30


Hello there! Welcome to our first Obi-Wan Kenobi discussion episode here on Ahch-To Radio! Thanks to travel, Celebration, & sickness, Alden & Nicky are here with a mega-chat on the first THREE episodes. A huge conversation on Obi, Vader, Leia, Reva, & all of the wonderful details in this show that have sent the Star Wars fandom buzzing. Yes, we even talk about Freck. What have you thought of this beautiful series thus far? How has Obi-Wan & Leia's relationship resonated with you? Let us know! Find Nicky on Instagram here, and on Twitter here. And be sure to hit up the Imperial Senate Pod's Patreon! Find them everywhere you get your podcasts, be it Apple Podcasts, YouTube, & more! Find this show @AhchToRadio on Twitter, Instagram, Facebook, and our new YouTube channel! And lastly, find Alden @ThatAldenDiaz on Twitter and Instagram! Find & support The Amidala Initiative on Twitter, and support the fundraiser benefitting Equality Texas on their GoFundMe page. #TransRightsAreHumanRights Check out the #BlackoutStarWarsEclipse campaign. Find out more by following the hashtag, checking out this article on Inverse, and reaching out to members of the LGBTQIA+ community. Ahch-To Radio is a Star Wars podcast feed fueled by the love of that galaxy far, far away. Creator/Host Alden Diaz dives into interviews, Star Wars origin stories, analyses, and more. It's all about the threads that make us connect with stories, and each other as fans. Plus, Ahch-To Radio is also home to our sister show, The Mandatorian Creed, hosted by Tori Fox! Tori explores various Star Wars topics with multipart breakdowns. And lastly, we also have our Star Wars Rebels rewatch show, A Rewatch Between Worlds, with Alden & Nicky Kumar!

ScienceLink
Highlights Día 3 Congreso Anual ASCO 2022

ScienceLink

Play Episode Listen Later Jun 6, 2022 32:27


El Dr. Enrique Isay Talamantes Gómez, oncólogo médico, jefe del servicio de Oncología Médica del Hospital de Gineco Obstetricia No. 3 del CMN “La Raza” del IMSS en la Ciudad de México, México, nos comenta en este podcast sobre los highlights del día 3 del Congreso Anual de la Sociedad Americana de Oncología Clínica 2022. Cáncer de próstata: ENZAMET: Estudio fase III, abierto, que aleatorizó a 1,125 pacientes con cáncer de próstata metastásico hormonosensible para evaluar la eficacia de enzalutamida vs. un antiandrógeno no esteroideo convencional combinado con terapia de privación de andrógenos de primera línea. TheraP: Estudio fase II, abierto, aleatorizado y multicéntrico de LuPSMA vs. cabazitaxel en pacientes con cáncer de próstata metastásico resistente a la castración que progresaron después de docetaxel. El objetivo de este estudio fue determinar la actividad y seguridad de la terapia con LuPSMA. CHART: Estudio fase III, abierto y multicéntrico de SHR3680 (un nuevo inhibidor del receptor de andrógeno oral) vs. bicalutamida en combinación con terapia de privación de andrógenos, que aleatorizó (1:1) a 654 pacientes con cáncer de próstata metastásico hormonosensible de alto volumen. Todos los pacientes tenían enfermedad de alto volumen adaptada del estudio CHAARTED. Los objetivos primarios fueron la supervivencia libre de progresión radiográfica evaluada por un comité de revisión independiente y la supervivencia global. Melanoma: KEYNOTE-716: Nuevos datos del análisis de supervivencia libre de metástasis a distancia y supervivencia libre de recurrencia (con un seguimiento más largo) del estudio fase III, aleatorizado (1:1), doble ciego, que evaluó a pacientes con melanoma estadio IIB-IIC resecado de alto riesgo que recibieron pembrolizumab o placebo. RELATIVITY-047: Primeros resultados de la tasa de respuesta objetiva analizada por factores de estratificación preespecificados, de la supervivencia global y de la tasa de respuesta objetiva de los subgrupos adicionales del estudio fase II/III, aleatorizado (1:1) de nivolumab en combinación con relatlimab vs. nivolumab en pacientes con melanoma metastásico o no resecable, sin tratamiento previo. Adenocarcinoma esofagogástrico: DANTE: Estudio fase II, multicéntrico, abierto, aleatorizado, que evalúo el tratamiento de atezolizumab perioperatorio en combinación con FLOT vs. FLOT sola en pacientes con adenocarcinoma esofagogástrico resecable localmente avanzado. Cáncer de pulmón: SKYSCRAPER-02: Primeros resultados del estudio fase III, doble ciego, aleatorizado, controlado con placebo, que evaluó la eficacia de tiragolumab (anti-TIGI) con atezolizumab + carboplatino y etopósido en pacientes con cáncer de pulmón de células pequeñas en estadio extenso no tratado. Abstract 8505: Estudio fase III, internacional, aleatorizado (2:1), doble ciego, multicéntrico, que evaluó el uso de serplulimab o placebo en pacientes con cáncer de pulmón de células pequeñas en estadio extenso que no habían recibido tratamiento sistémico previo. El objetivo primario fue la supervivencia global y los secundarios fueron la supervivencia libre de progresión, la tasa de respuesta objetiva, la duración de la respuesta y la seguridad. Fecha de grabación: 05 de junio de 2022. Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material

Bounty Hunt: A Star Wars Podcast by Youtini
Ep. 52: Obi-Wan Kenobi - Part I, II, III

Bounty Hunt: A Star Wars Podcast by Youtini

Play Episode Listen Later Jun 6, 2022 117:25


Star Wars: Obi-Wan Kenobi has finally arrived into our lives. Strap in for recaps of parts I, II, and III while we give our thoughts and expectations of the series to come. ** Below, more Star Wars we have ** ------------------------------------------------------------------------------------------------------- JOIN OUR COMMUNITY ▶ WEBSITE https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbDNRUjdRV3NwQUdQTzZ4cWZlZEg0dDNnRmRpd3xBQ3Jtc0tralo0N0FzTmZGSDBRRE9adVVDaE9pZUFLcHRXZ1RkQXA1cTZpdGhHUmdHVlQ0Q1hsRFduWXpyYUhsNzAxMUxIQ09yMGJybWlKWmM3TDVCMzdPVjRWQUdZV19leUVCeXJyWWJUaHhmWllYVDNGb0hJSQ&q=https%3A%2F%2Fwww.youtini.com%2F&v=4PU6I3-nF_I (https://www.youtini.com) ▶ DISCORD https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbmlIQ1d6WlgwYXZiR3pVQXFlZ2t1V0EwdDVpZ3xBQ3Jtc0trTDVGU2xCTnIxR0UwSFp4S05ST2NOc0xzRXVMNU56S2syZ1k4VjBGdWFMMWhTaUdaNzZOM01EX3c2THp0aGRKazB2aGFobnRFd0p4ZWE1elFHbzhTcUhhSGhlVWRzUzNhb1RSaG8xaTYyWEFIVkRuSQ&q=https%3A%2F%2Fwww.youtini.com%2Fdiscord&v=4PU6I3-nF_I (https://www.youtini.com/discord) ▶ TWITTER https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbU1oRlNjY29KeUlpMGY5N1A5OU9jdXN0SFJRQXxBQ3Jtc0ttcDl2cGxVcm84eUkwMzRQTFFPYzYtMXhaWlNUTUlrNlhNa0JhdkVtZXlMcDlMS1hXbGxUS3JtbGJGQ3RVTUZaaUZXYzUwRnhXaUZodHBTbDBCc2x1RnRDcTJxbEd0MC0yUVExczBJVDBidHNoOTFrRQ&q=https%3A%2F%2Ftwitter.com%2Fyoutini_us&v=4PU6I3-nF_I (https://twitter.com/youtini_us) ▶ INSTAGRAM https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbWtERGtDM0xvWUcyc3JfQzF4Uzkzc05ZQldUQXxBQ3Jtc0tuREJ6WkpyZG41LWdkWTF4LVJwT2hqeGE5RjVLV3R0LTVWV0VPZ2VtQWVZaFktTWJXTUtTODY5ZWhhcHgteHFuelV2VFdYWWtLaERQaEtpVjFGVGZfUWE2aC16SVoyOUF0NTEtTl9ObTR1blFlSWh6bw&q=https%3A%2F%2Fwww.instagram.com%2Fyoutini_us%2F%3Fhl%3Den&v=4PU6I3-nF_I (https://www.instagram.com/youtini_us/...) ▶ FACEBOOK https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbUZQM3B6NmZUeHJDcEVmcEhBWVhKN2VBUUpjZ3xBQ3Jtc0tsS2x6TzdKbjFxQTRCX0tMX1RwYV9wT0FkbXFuSV9GZl9JaEdlTEMyVk5qMl93eDBEZTY3RU9VTEwzZGlUZk95NVBYVldUeE55Nm9wb0JzajUzSHhKZmctMkRhdG9LVG9Xaml4V21sSWZJQXg4OGthTQ&q=https%3A%2F%2Fwww.facebook.com%2Fyoutini&v=4PU6I3-nF_I (https://www.facebook.com/youtini) ------------------------------------------------------------------------------------------------------- SUPPORT YOUTINI ▶ WEEKLY CONTENT ON PATREON: https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbDFJN0o5RXBLSkVMY1pRcEFUX0Vobld1cjU2UXxBQ3Jtc0ttSXJ1YXl1TnNmSzJjTmRQc3liZFlrd092OXFMb1NjdFlOSlpqZ3RJU25KaFBtcy1aeUJaaXMtMkF6WFFodUdUaDRrN29mcnFsaEJxbTRtMGQxMjYxMENVbE9oR2dXdHMyem5ORmRrajd3R3hVUUlsbw&q=https%3A%2F%2Fwww.patreon.com%2Fyoutini&v=4PU6I3-nF_I (https://www.patreon.com/youtini) ▶ YOUTINI MERCH: https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa1IxTGNrQkktb3VVTDZOQkt0SGN5Ul81bmlhd3xBQ3Jtc0tuMWxCZy1QbVBKdl9hOFo3alpBSEREZHRER19jNjlxMnlhcEZaNVRjSHVmbzNFMDlOdGlHTGl1MVo0dTZrdVc1YXRPWFJGOW5fNXhjM0Z0VnhiWUdsM3RBR3RQR2JOeUtNY0c2N2JLcW1SY2JubjNJZw&q=https%3A%2F%2Fwww.youtini.com%2Fmerch&v=4PU6I3-nF_I (https://www.youtini.com/merch) ------------------------------------------------------------------------------------------------------- GET MORE STAR WARS BOOKS ▶ Get A FREE Star Wars Audiobook: https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa0tkTWxXa3JXQVEtektnQkF2RDBuQThpUGhxZ3xBQ3Jtc0tuYU1lZXVLcktFS1BPcVVfQUQ3WDlESHdGVVZxdEtjeFJsYUlrdDgzLThFSEZxcWNGbUVyejFLREdrN3Rza2JCVkM1dTRQT0ROV1dWcmk0eDgzNUlTRDFjaUhTc2c2OFpXS3NZWGEzNGs0Y0RhdlBudw&q=https%3A%2F%2Fwww.youtini.com%2Faudible&v=4PU6I3-nF_I (https://www.youtini.com/audible) ▶ Best Canon Book To Read First:...

Emerald Bay Community Church Video
James I, II, III John - Lesson 12 and 13

Emerald Bay Community Church Video

Play Episode Listen Later May 29, 2022 49:59


Walking in the Truth ( II John) The Obligation of Christian Hospitality ( III John)

Edengrove Presbyterian Church
32 Of the State of Man After Death & of the Resurrection of the Dead II-III - This We Confess Podcast

Edengrove Presbyterian Church

Play Episode Listen Later May 28, 2022 19:07


What will our final state be like?

This We Confess
32 Of the State of Man After Death & of the Resurrection of the Dead II-III - This We Confess Podcast

This We Confess

Play Episode Listen Later May 28, 2022 19:07


What will our final state be like?

Emerald Bay Community Church Video
James I, II, III John - Lesson 10 and 11

Emerald Bay Community Church Video

Play Episode Listen Later May 22, 2022 41:39


The Nature of Divine Love (I John 4) The Results of Faith in God (I John5)

Lament & Hope: Prayers & Teaching for Justice and Peace
The Ancient Story - Acts I, II, III, IV, V

Lament & Hope: Prayers & Teaching for Justice and Peace

Play Episode Listen Later May 22, 2022 15:14


Words and voice- Jon SwalesMusic, Various 'Chris Sayburn' used with permission.A poetical exploration of the biblical story. See https://docs.google.com/document/d/1-lzptELp2r5yxsiv0Qm_J6pZRuTegky9jSvDmzSEC2k/edit?usp=sharing

Wrestling with Theology
Confessional Corner: The Messy Business of the Mass and Monks (SA II II-III)

Wrestling with Theology

Play Episode Listen Later May 16, 2022 35:02


The papistic Mass conflicts with the chief article of the Christian faith on the most basic level. Monasteries were originally established as places for advanced theological education. Subscribe on Spotify (https://open.spotify.com/show/27tIOK9gdKZ0HrEgIJ4DiJ) or your favorite podcast app.

Emerald Bay Community Church Video
James I, II, III John - Lesson 9

Emerald Bay Community Church Video

Play Episode Listen Later May 15, 2022 46:46


The Impact of Christian and Divine Love (I John 3-4)

Emerald Bay Community Church Video
James I, II, III John - Lesson 8

Emerald Bay Community Church Video

Play Episode Listen Later May 8, 2022 44:10


The Benefits of the Children of God (I John 2:28-3:10)

Emerald Bay Community Church Video
James I, II, III John - Lesson 7

Emerald Bay Community Church Video

Play Episode Listen Later May 1, 2022 47:32


True Fellowship With God - (John 1:1-2:11 Last Days of Christ on Earth after the Resurrection A Full Study Session of this Topic in in Men's Bible Study.

Join the Party
Afterparty: Join Us I, II, III

Join the Party

Play Episode Listen Later Apr 19, 2022 59:15 Very Popular


How do you build a massive mountain lobster? How long did we know that some folks were pixelated? And what hot dogs are the best hot dogs? All that and more on the Afterparty!   Here's the Shadow of the Colossus D&D zine, a completo, Crif Dogs, and a Seattle dog.    Sponsors - Hero Forge, where you can now get Color Standees! Visit heroforge.com to start designing your custom miniature today. - Squarespace. Go to squarespace.com/jointheparty for a free trial, and when you're ready to launch, use offer code JOINTHEPARTY to save 10% off your first purchase of a website or domain.  - BetterHelp, a secure online therapy service. Get 10% off your first month at betterhelp.com/jointheparty   Find Us Online - website: jointhepartypod.com - patreon: patreon.com/jointhepartypod - twitter: twitter.com/jointhepartypod - facebook: facebook.com/jointhepartypod - instagram: instagram.com/jointhepartypod - tumblr: jointhepartypod.tumblr.com - merch & music: jointhepartypod.com/merch   Cast & Crew - Dungeon Master, Co-Producer: Eric Silver - Co-Host (Milo Lane), Co-Producer, Editor, Sound Designer, Composer: Brandon Grugle - Co-Host (Aggie O'Hare), Co-Producer: Amanda McLoughlin - Co-Host (Val Vesuvio), Co-Producer, Editor: Julia Schifini - Multitude: multitude.productions   About Us Join the Party is a D&D actual play podcast with tangible worlds, genre-pushing storytelling, and collaborators who make each other laugh each week. We welcome everyone to the table, from longtime players to folks who've never touched a roleplaying game before. Begin with Campaign 2 (The Join Campaign) for a modern, sci-fi superhero game, or marathon all of Campaign 1 (The Party Campaign) for a high fantasy story. And once a month we release the Afterparty, where we answer your questions about the show and how we play the game. New episodes every Tuesday.

Emerald Bay Community Church Video
James I, II, III John - Lesson 6

Emerald Bay Community Church Video

Play Episode Listen Later Apr 10, 2022 50:28


Last Days of Jesus through Good Friday. The Light of Christ's Love (I John 1:1 - 2:11)

Emerald Bay Community Church Video
James I, II, III John - Lesson 5

Emerald Bay Community Church Video

Play Episode Listen Later Apr 3, 2022 44:26


Emerald Bay Community Church Video
James I, II, III John - Lesson 3

Emerald Bay Community Church Video

Play Episode Listen Later Mar 20, 2022 50:33


Supernatural Confessions
#125 - Grandma Stories Part II & III | Fav. Moustache | Saw the DEAD (Wednesday Podcast)

Supernatural Confessions

Play Episode Listen Later Mar 9, 2022 32:44


This week we continue with anonymous' story from his grandma in 2 part. Last part was posted last week, click here to listen! In both of his story today, the entity is of the same type, also the name that we are all quite familiar with, Pontianak! Embalmers have a task that not everyone can do. (I know for sure, I couldn't!) Preparing body from top to bottom, to make sure that they look nice for their final days. Dealing with the dead, almost everyday, there must be some scary stories no? This story is not scary to say, but rather unusual. Two confessors told us stories about how they (or mother) encountered the dead. Of course not knowing that they are dead for they appear like themselves, like any other day! It must be the hantu (ghost)! Links: You can submit your confession here: Supernatural Confessions You can join our Facebook group here: SC Private Group, It must be the Hantu

XXY梗你看電影
【H&M 365】EP. 33 加特洛夫事件 - 最離奇的山難,你相信哪個詭扯淡? / 《詭山》Devil's Pass, 2013

XXY梗你看電影

Play Episode Listen Later Feb 2, 2022 15:37


小額贊助支持本節目: https://pay.firstory.me/user/xxymovie 留言告訴我你對這一集的想法: https://open.firstory.me/story/ckz2ignl512v80892nm47bxr8?m=comment 【H&M 365】#PODCAST 加特洛夫事件 - 最離奇的山難,你相信哪個詭扯淡? 《詭山》Devil's Pass, 2013 . ▶ 收看YouTube影像:https://youtu.be/ISMN58Nk7wc ▶ 收聽PODCAST聲音:https://open.firstory.me/story/ckz2ignl512v80892nm47bxr8/platforms . 1959年2月2日晚間,十名具有II級登山證書、經驗豐富的登山好友們,為了取得III級登山證書而前往前蘇聯北烏拉山脈,挑戰當地原住民口中的「死亡之山」 Kholat Syakhl;一行人由隊長 加特洛夫(Dyatlov)帶隊,花了2天的旅途來到目的地。中途一位成員因風濕而退出,卻沒想到這是最後一次與另外九位好友們見面的時刻。 . 登山的九人在20日後失聯,六天後,他們的營地被搜救隊發現,但現場帳篷從裡而外被割開,重要的食物、保暖衣物都留在帳篷內;帳篷外有凌亂的腳印往東北方的森林延伸,搜救隊隨著腳印找到了九位罹難者遺體。 . 九人的死狀悽慘,他們穿著單薄衣物、赤腳、曾有爬樹的跡象;還有人身體遭受到嚴重撞擊的外傷、顱骨粉碎,皮膚呈現不自然的黃褐色;甚至有兩人的雙眼、一人的舌頭消失;更令人匪夷所思的是,有四人的衣物被檢測出具高度輻射反應。總總讓人不解的現象,加上缺乏目擊者,讓這起山難事件成為歷史懸案。 . 蘇聯的調查人員在1959年5月宣布加特洛夫事件調查終結,以「強大的未知力量」草草結案,調查報告被列為機密文件封存。直到蘇聯解體後,調查報告公開,但部分頁面已遺失。2020年7月11日,負責此案的檢察官 古恩諾夫,正式宣布加特洛夫事件主因為雪崩;他表示,這九位罹難者在遭遇雪崩後,匆忙逃離帳篷後,並在附近的石脊下避難,但因返回營地時迷途而失溫死亡。然而,諸多疑點仍無法被解釋,因此加特洛夫事件仍是不少超自然現象愛好者或陰謀論者熱烈討論的話題。如今,加特洛夫事件發生的所在地,被命名為「加特洛夫山口」,設有紀念碑供人弔念。 . 2013年上映的《詭山》,是根據加特洛夫事件為背景,採偽紀錄片的形式呈現的恐怖電影;故事描述五位前往加特洛夫事件發生地探險的美國電影系大學生,試圖藉由拍攝紀錄片解開這個超過半世紀的歷史懸案。然而,在他們越深入這座死亡之山就遇到越多詭異事件,讓這場探險逐漸失控。 . . 更多詳細內容,請收聽PODCAST完整內容;【H&M 365】是一個日更聲音節目,用365天的篇幅,每天分享一則歷史故事和一部影劇作品,帶您了解歷史上發生哪些重要的事件唷!如果喜歡我的節目,也別忘了在APPLE PODCAST上留下五星評價,並利用各大社群平台推薦分享我的節目,或是有任何想法都歡迎留言給我與我討論唷! . . #電影 #歷史 #點評 #影評 #知識 #解析 #movie #歷史上的今天 #History #movies #加特洛夫事件 #迪亞特洛夫事件 #詭山 #蘇聯 #山難 #外星人 #陰謀論 #DyatlovPassIncident #DevilsPass ************** 歡迎加入【有梗電影俱樂部】,不錯過任何電影資訊或線上線下活動喔! 臉書社團(需回答問題審核):https://www.facebook.com/groups/viewpointmovieclub DISCORD群組:https://discord.gg/KR5XzsmW 別忘了追蹤XXY的電影相關文字、影像、聲音創作唷!

The Moonstone by Wilkie Collins
32 – Second Period: 2nd Narrative: Chapters II-III

The Moonstone by Wilkie Collins

Play Episode Listen Later Dec 1, 2021 34:31


More great books at LoyalBooks.com

CultureCast
The Metaverse and the Enlightenment Part II, III

CultureCast

Play Episode Listen Later Nov 28, 2021 74:14


In this episode, I continue to trace the intellectual roots of the Metaverse and the current “toxic” moment in human history in which intellectual trends of the past have reached a culmination. I discuss the rationalist system of Descartes and Christian Wolff, who tries to form a scientia with reason alone. The age of Reason replaces the age of Faith by using reason alone, without revelation and faith, to gain full deductive cognition of reality. In Part III, I explore how Hume debunks the idea of causality which is central to the Newtonian system. Causality is not something metaphysically robust in the world and we can't seduce it rationally. Instead, causality is a psychological habit by which we associate events with no necessary logical connection. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

BOBS MESS PODCAST
Ep 26 Exploitation Horror: Tusk, The Human Centipede I II III, And A Serbian Film

BOBS MESS PODCAST

Play Episode Listen Later Nov 13, 2021 56:54


On this episode of Bobs Mess I'm once again joined by Macabre Mary to discuss the exploitation horror movies Tusk, The Human Centipede films I II III and last but not least A Serbian Film. You can find Mary on Twitch https://www.twitch.tv/realmacabremary and everywhere else on social media @RealMacabreMary FOLLOW ME ON TWITTER @bobsmesscast FOLLOW ME ON INSTAGRAM @bobsmesspodcast FOLLOW ME ON YOUTUBE https://www.youtube.com/channel/UC2BTSBhfOEZK-loC6EEQLXA --- Support this podcast: https://anchor.fm/bobsmesscast/support

Mat Time
Mat Time - Episode 5 Region II & III - AA/A & AAA

Mat Time

Play Episode Listen Later Apr 8, 2021 28:59


In this episode, the guys preview Regions II and II in both AA/A and AAA respectively!